Liver and atherosclerotic risks of patients with cryptogenic steatotic liver disease
Journal
Hepatology international
Date Issued
2024-01-16
Author(s)
Abstract
In 2023, a new nomenclature of "metabolic associated steatotic liver disease" (MASLD) has emerged by incorporating cardio-metabolic criteria to redefine "non-alcoholic fatty liver disease" (NAFLD). Among steatotic liver disease (SLD), those having no known causes and without any one of cardio-metabolic criteria are deemed to have cryptogenic SLD. This study aims to compare the liver and atherosclerotic risks between MASLD and cryptogenic SLD patients.
Subjects
Metabolic associated steatotic liver disease; Metabolic dysfunction; NAFLD fibrosis score; Non-alcoholic fatty liver disease; Steatotic liver disease
SDGs
Type
journal article